OBJECTIVES: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) with approximately 1,000 to 1,500 new cases diagnosed each year in the United States (US). Trisenox (arsenic trioxide, ATO) is currently licensed for the treatment of patients with APL who are refractory to, or have relapsed from previous treatment with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. This analysis evaluated the cost-effectiveness of ATO+ATRA in the treatment of newly diagnosed low-to-intermediate risk APL in adult patients, compared to two other widely used regimens: ATRA+Ara-C+chemotherapy, and ATRA+Idarubicin (AIDA). Cost-effectiveness was measured as incremental cost per quality-adjusted life year (QALY) gained and per incremental cost per life year (LY) saved from a third-party payer perspective in the US. METHODS: A Markov cohort model with monthly cycles and four health states (1st-line stable disease, 2nd-line stable disease, 2nd-line disease event, and dead) was developed. Patients in the model begin treatment at age 45 and were followed until death. Eight months duration of ATO+ATRA was compared to either 15 months of ATRA+Ara-C+chemotherapy or 33 months of AIDA. Efficacy data (event-free survival.overall survival) were obtained from key clinical trials. Quality of life/health utility data were obtained from the literature. Costs were obtained from standard US data sources. Transition probabilities were estimated by calibrating the model to eventfree and overall survival Kaplan-Meier curves for each treatment. Deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Compared to ATRA+Ara-C+chemotherapy, ATO+ATRA had incremental cost effectiveness ratios of $5,900/QALY gained and $4,800/LY saved. ATO+ATRA weakly dominated AIDA (had a lower incremental cost-effectiveness ratio and more QALYs and LYs) in newly diagnosed patients. The results were robust to sensitivity analysis. CONCLUSIONS:
OBJECTIVES: In ALSYMPCA, radium-223+BSoC significantly prolonged overall survival by 3.6 months (HR= 0.70; 95% CI, 0.58-0.83; P< 0.001). Analysis of prospectively collected medical resource utilization (MRU) data from ALSYMPCA demonstrated that radium-223+BSoC vs BSoC reduced overall MRU, including number of hospitalization days/patient/year (8.1 vs 14.6; P< 0.001). An existing cost-effectiveness analysis (CEA) model was modified by incorporating the prospective MRU data from ALSYMPCA to evaluate their effect on estimated cost-effectiveness of radium-223+BSoC vs placebo+BSoC in Canada. METHODS: A Markov model was developed with 5 health states, reflecting disease progression and SSEs. The Canadian payer perspective was used. Quality of life data were from ALSYMPCA; cost inputs were from recognized Canadian sources. Costs and outcomes were discounted at a 5% annual rate. Model time horizon was 5 years. RESULTS: Incorporating MRU data reduced the incremental cost estimate by $11,065 relative to CEA without MRU data and improved the incremental cost-effectiveness ratio for radium-223+BSoC vs placebo+BSoC by ~35% to $73,408 ($20,098 incremental cost, 0.274 quality-adjusted life years [QALYs] gained), substantially lower than the frequently referenced, although not explicitly stated, Canadian cancer drug threshold ($100,000/QALY). Sensitivity analyses demonstrated robustness of cost-effectiveness results. Patient management costs were affected primarily by differential hospital utilization between treatment groups. CONCLUSIONS: Including directly observed MRU data in this model markedly improved the impact of radium-223 vs modeled benefits alone, confirming its cost-effectiveness as a treatment for CRPC with symptomatic bone metastases and no visceral metastases. Reduced hospital utilization with radium-223 may be driven by delays in time to symptomatic skeletal event (SSE) and reduced hospitalization days/patient/year after SSE (Cislo et al. ASCOQCS 2014) . Gai R. National Center of Child Health and Development, Tokyo, Japan OBJECTIVES: To evaluate cost-effectiveness of different HPV vaccination as alternatives or additions to the current screening program to prevent and control cervical cancer in Mainland China. METHODS: A Markov model was developed for a cohort of 100,000 12-year-old girls to simulate the natural history of low risk and high risk to HPV infection and its progress to cervical cancer or genital warts. Three recommended screening (protocol 1. Liquid-based cytology test + HPV DNA test; protocol 2. Pap smear cytology test + HPV DNA test; protocol 3. Visual inspection with acetic acid) and two types of HPV vaccination programs (bivalent and quadrivalent vaccines) were incorporated to the two kinds of HPV vaccines. Input data were obtained from literature review, national databases, and a field study. Sensitivity analyses tive. METHODS: We compared ipilimumab treatment for advance melanoma with other drugs for advanced cancer that met inclusion criteria including: (1) positive phase three study with overall survival as primary or secondary aim, (2) authorized by Chilean government agency, and (3) verifiable price in the private market. We performed a cost -efficacy analysis, using local prices obtained from published local sources to calculate an average cost to progression. Time to progression was obtained from published clinical trials. Mean overall survival improvement was used as the efficacy metric. Cost -efficacy outputs were plotted and compared. All costs are presented in 2014 USD. Additionally, a survey to Chilean oncology specialist was designed to obtain qualitative information about their experience(s) with ipilimumab for the treatment of metastatic melanoma patients in Chile. RESULTS: Nineteen drugs met inclusion criteria with 28 advance cancer indications. The average cost per month of mean survival improvement was estimated at $24,802 (range 1,737 -$91,256). We estimated the cost per additional month of mean survival improvement at $13,122 and $14.843 for first and second line treatment with ipilimumab respectively. Based on the survey, local expert opinion unanimously stated that ipilimumab is the best treatment alternative for patients with advanced melanoma. CONCLUSIONS: Compared with other innovative drugs for the treatment of advanced cancers, the cost per mean survival improvement with ipilimumab was below the average market value and may provide good value for money from a third payer perspective in Chile. Based on the survey, specialists noted ipilimumab as the best treatment option for Chilean patient with advanced melanoma. 
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Cost-EffECtivENEss ANAlysis of fEmAlE humAN PAPillomAvirus vACCiNAtioN iN mAiNlANd ChiNA
PCN71 BEvACizumAB for froNt-liNE trEAtmENt of EPithEliAl ovAriAN, fAlloPiAN tuBE or PrimAry PEritoNEAl CANCEr PAtiENts With high risk of rElAPsE: A Cost EffECtivE oPtioN for CANAdiAN PAtiENts
Hoffmann-La Roche, Basel, Switzerland
OBJECTIVES: In the ICON7 randomized controlled trial, Oza et al. reported that the 502 front line ovarian cancer patients who were at a high-risk of relapse, that is patients with stage III suboptimal debulking, stage III unresectable or stage IV disease, could benefit most effectively from the addition of bevacizumab (7.5mg/kg) to chemotherapy (carboplatin, paclitaxel), compared to chemotherapy alone in the front line setting. The objective of this study is to investigate the cost effectiveness (CE) of this proposed change in treatment practices. METHODS: Long-term PFS and OS were predicted using log-logistic time-to-event parametric functions over a time horizon of 10 years. Canadian PFS health state utility values were obtained from the mapping of EQ5D scores from ICON7's high risk patient population. Post progression utility values were derived from Naik et al (2014) Canadian study. The cost inputs, including standard resource use practices, for this CE model were informed from public sources, gynecological oncology experts and ICON7. An annual 5% discount rate was applied to both efficacy and costs. A probabilistic sensitivity analysis (PSA) as well as one-way sensitivity analyses were conducted. RESULTS: The ICON7 highrisk patients receiving bevacizumab plus chemotherapy had a mean LY gain of 5.8 months compared to patients on chemotherapy alone, and a mean QALY gain of 4.5 months. This resulted in an ICER of $74,084CAD per LY gained and $96,261CAD per QALY gained. 55% PSA simulation of the QALY ICERs were at $100,000CAD or less. CONCLUSIONS: Although no formal willingness-to-pay threshold exists for health technology assessments in Canada, $100,000CAD has been estimated for oncology drugs. At a $100,000CAD threshold, bevacizumab in addition to chemotherapy provides a cost-effectiveness alternative for high-risk patients (i.e. stage III suboptimal debulking, stage III unresectable or stage IV) with ovarian cancer in the front line setting.
PCN72 iNdirECt Costs AmoNg mEtAstAtiC BrEAst CANCEr PAtiENts rECEiviNg EriBuliN
Wan Y. 1 , Copher R. 2 , Corman S. 1 , Abouzaid S. 2 , Gao X. 1 1 Pharmerit International, Bethesda, MD, USA, 2 Eisai, Inc., Woodcliff Lake, NJ, USA OBJECTIVES: This study examined indirect costs in terms of productivity loss among patients who received eribulin vs. other commonly used chemotherapies in the treatment of metastatic breast cancer (MBC). METHODS: The MarketScan Health and Productivity Management Database (2008-2012) was used. Patients who initiated eribulin, or received single-agent gemcitabine/capecitabine/vinorelbine as the last chemotherapy during the index period (July 2008-Nov 2012) were defined as each corresponding study cohort. Adult MBC patients eligible for ≥ 1 month employee benefits of short-term disability (STDI) were identified. Difference in STDI days was compared between study cohorts using Wilcoxonrank-sum-test. STDI-related costs were estimated by multiplying leave days by median weekly wages. Two-step generalized linear models were used to estimate adjusted indirect costs by controlling for age, payer, region, comorbidities, prior chemotherapy, and hormone therapy. RESULTS: A total of 43 patients receiving eribulin, 99 gemcitabine, 54 vinorelbine, and 303 capecitabine were eligible for STDI (mutually exclusive). Eribulin patients had either similar (vs. gemcitabine or vinorelbine) or more (vs. capecitabine) chemotherapy agents prior to initiating index treatment. Eribulin patients had either numerically lower or similar STDI days per-patient-per-month compared to those receiving other therapies (6.2±10.8 vs. 8.8±11.0 [gemcitabine], P= .055; 7.1±10.3 [vinorelbine], P= .201; 6.1±9.2 [capecitabine], P= .295). In addition, eribulin (vs. gemcitabine) patients were less likely to have any STDI leave (30% vs. 53%, P= .014). The adjusted mean indirect costs associated with STDI per-patient-per-month were $720 (95% CI: $470-$1,102), $944 (95% CI: $595-$1,175), $837 (95% CI: $744-$1,198) and $635 (95% CI: $536-$753) for eribulin, gemcitabine, vinorelbine and capecitabine patients, respectively. CONCLUSIONS: Productivity loss, as measured by utilization of STDI and associated costs, tended to be lower in MBC patients treated with eribulin vs. gemcitabine and similar to vinorelbine or capecitabine.
setting, there is a need for additional information on the clinical and economic impact of idelalisib to inform decisions about utilization, coverage, and reimbursement. OBJECTIVES: The objective of this study was to evaluate the costeffectiveness of idelalisib plus rituximab versus rituximab alone from a payer's perspective. METHODS: We developed a partition survival model to evaluate idelalisib plus rituximab versus rituximab alone. The model included three health states -Pre-Progressed, Progressed, and Death. The pivotal trial Study 116 (Furman et al., 2014) served as the basis for this study by providing data on Progression-Free-Survival (PFS) and Overall-Survival (OS), dosing, and adverse events. We used longer-term data from a trial of bendamustine plus rituximab in CLL plus Weibull cumulative distribution functions to extrapolate incomplete PFS and OS curves. Cost data was derived from Wolters Kluwer Health, Centers for Medicare and Medicaid Services data, and publicly available literature. One-way and probabilistic sensitivity analyses were performed to evaluate uncertainty. We used a lifetime horizon, payer perspective, and a 3% discount rate. RESULTS: Total costs were $585,493 and QALYs were 3.34 for the idelalisib plus rituximab group, while total costs were $66,698 and QALYs were 1.20 for the rituximab alone group. This yielded an incremental cost-effectiveness ratio of $242,884/QALY. The result was most sensitive to changes in the hazard ratio for death and idelalisib drug costs. The probability that idelalisib was cost-effective was 1% at both a willingness to pay of $100,000/QALY and $150,000/QALY. CONCLUSIONS: Idelalisib plus rituximab does not appear to be cost-effective since it greatly exceeds the commonly cited thresholds of $100,000/QALY and $150,000/QALY. However, it is in line with other commonly used treatments in cancer.
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Cost-EffECtivENEss of Eml4-Alk gENE tArgEtEd first-liNE CEritiNiB trEAtmENt AmoNg PAtiENts With AdvANCEd Alk-PositivE NoN-smAll CEll luNg CANCEr
Upadhyay N. , Atreja N.
University of Houston, Houston, TX, USA
OBJECTIVES: Mortality associated with the lung cancer is maximum among all forms of cancer in the US. Among all lung cancer patients, 85% have non-small cell lung cancer (NSCLC). Of these NSCLC patients, 5% are EML4-ALK gene positive patients. In these patients, standard therapy [platinum doublet (cisplatin and gemcitabine) as first-line therapy, pemetrexed as second-line therapy, and erlotinib as third-line therapy] has shown plateau effect. In 2014, FDA has approved Ceritinib as a first line therapy based on the results from phase one study, under the orphan drug category for ALK+NSLCC. Study aims to evaluate the cost-effectiveness of EML4-ALK fusion targeted ceritinib treatment as compare to treatment by standard therapy among ALK+NSCLC patients in the US. METHODS: A decision analytic model with the embedded Markov model was developed to compare the lifetime benefits in terms of quality adjusted life years [QALYs] and direct medical costs of the treatment strategies for patients with advanced NSCLC. Progression free survival rate during each treatment alternatives, rates of adverse events, mortality rates, and utility values on standard therapy and ceritinib were obtained from published literature. Cost inputs were based on 2013 Medicare reimbursement rates. Primary outcome of incremental cost effectiveness ratio (ICER) was estimated as an incremental cost of treating with Ceritinib per QALY gained. USD 100,000 was considered as the willingness to pay threshold. RESULTS: The use of EML4-ALK targeted ceritinib treatment for EML4-ALK-positive advanced NSCLC results in added benefits (0.09 QALYs) and extra costs ($1897.82) for the average patient with NSCLC. The ICER was $21,263 for per QALY gained. CONCLUSIONS: Study suggests that the treatment by Ceritinib compared to the treatment by standard therapy alone is a cost-effective strategy based upon the decision analysis model. Study limitation includes non-inclusion of the cost of EML4-ALK gene testing, which could change the total treatment cost significantly. Medicine, Istanbul, Turkey, Istanbul, Turkey, 4 Medipol University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, 5 Acibadem University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey OBJECTIVES: Sorafenib is the first product approved for treatment of RAI refractory locally advanced/metastatic DTC patients. This study was conducted in order to analyze cost-effectiveness of sorafenib for treatment of patients with RAI refractory locally advanced/metastatic DTC in Turkey. METHODS: A cohort partition model assigning patients to one of three health states according to the proportion of patients who are progression-free, progressed, or dead in each 28-days cycle was adapted to Turkish setting. The incremental cost-effectiveness ratios (ICER) were calculated per quality-adjusted life years (QALYs) and life-years (LYs) gained. Turkish payer's perspective was taken and time-horizon was set as patient's lifetime (maximum 30 years). Sorafenib was compared to the best supportive care (BSC) within the model since there are no agents for treatment of patients on this stage of the disease. Essential clinical inputs were derived from DECISION trial and local resource-utilization data were based on expert opinions through an expert panel. Sensitivity of the results was evaluated in terms of key inputs by deterministic oneway and probabilistic sensitivity analyses. All costs were calculated in Turkish Liras (TL) and converted to USD using TL/USD currency rate as 2.2 (mid-2014). RESULTS: Total cost of sorafenib-treated patients is 24,384 USD higher compared to BSC. Besides, sorafenib is associated with increments of 1.29 LYs and 0.80 QALYs compared to BSC. The ICER of sorafenib per LYs and QALYs gained compared to BSC were determined as 18,851 USD and 30,485 USD respectively. One-way sensitivity analysis demonstrated that results are not sensitive to the changes in model inputs were performed on key variables and different vaccination scenarios. RESULTS: With 20% screen coverage and 20% vaccine coverage, quadrivalent vaccine plus screening by protocol 2 had the most attractive cost-effectiveness ratio ($6,691 per QALY saved) compared to when using a willingness to pay (WTP) for a QALY threshold of $22,433 (three times of GDP per capita in China). The bivalent vaccine and its combination with the screening program could reduce much more incidence and mortality of cervical cancer compared to the quadrivalent vaccine, while the cost per QALY acquired of the quadrivalent vaccine is lower. The combined strategies are cost-effective compared to the counterparts of vaccination alone and can achieve much more health benefits compared to screening alone. The coverage of the screening and the vaccination serve as a crucial factor of variations in the costeffectiveness of different strategies. CONCLUSIONS: HPV vaccinations integrated into the current screening programs are cost-effectiveness strategies, and should be considered a potential strategy to reduce disease burden of cervical cancer in China. Selection of the appropriate strategy can be flexible for policy makers, because of geographical and socioeconomic diversities. Rocha J. , Vanhuyse M. , Aprikian A. , Cury F. , Kassouf W. , Dragomir A. McGill University Health Centre, Montreal, QC, Canada Abiraterone acetate (Abi) therapy showed survival and clinical benefits in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in phase III trials. In Quebec, Abi reimbursement was approved for docetaxel-naïve and refractory patients in 2014 and 2012, respectively.OBJECTIVES: Evaluated the cost-effectiveness and survival impact of Abi treatment in the management of CRPC post-docetaxel. METHODS:
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Cost-EffECtivENEss of sorAfENiB for trEAtmENt of rAdioACtivE iodiNE (rAi)-rEfrACtory loCAlly AdvANCEd/mEtAstAtiC diffErENtiAtEd thyroid CANCEr (dtC) iN turkEy
PCN77 usE of ABirAtEroNE iN thE mANAgEmENt of CAstrAtioN-rEsistANt ProstAtE CANCEr: A rEAl-lifE Cost-EffECtivENEss study
The study cohort was selected from the public healthcare insurance programs: Régie de l'Assurance Maladie du Québec (RAMQ) and Med-Echo databases. It consisted of patients with CRPC starting chemotherapy or abiraterone treatments beteween 2009-2010 (docetaxel), defined as pre-Abi era, and 2012-2013 (docetaxel+Abi), defined as Abi era. Survival was evaluated by Kaplan-Maier and the difference in survival between pre-Abi and Abi eras by log-rank test. Association between Abi exposure and survival was evaluated by cox proportional hazards model adjusted for co-variables. The incremental cost-effectiveness ratio was obtained by dividing changes in costs (Docetaxel alone, Docetaxel+Abi) and survival in the two periods. RESULTS: Survival was significantly increased by the addition of Abi to CRPC management. Mean survival were 11.47 (±0.6; N= 115) vs 15.26 (± 0.85; N= 67) months in the pre-Abi vs Abi era (p< 0.001). Mean treatment duration for Abi was 163 days (±108.7) and for chemotherapy during Abi period was 4.4 cycles (±3.1) and 4.6 clycles in the pre-Abi era (±4.2). The adjusted harzard ratio when comparing pre-Abi vs Abi era was 1.32 (95%CI 0.98-1.78). The cost per patient for docetaxel treatment was $3,680 and for docetaxel+Abi was C$49,650. As expected, the addition of Abi resulted in a cost increment of C$45,970/patient. The incremental cost-effectiveness ratio was C$145,569 per life-year gained. CONCLUSIONS: Our real-life study indicates that patients receiving Abi plus docetaxel had a survival benefit when compared to chemotherapy alone. Addition of Abi was associated with an important increase in CRPC therapy costs.
PCN78 Cost EffECtivENEss ANAlysis of EriBuliN mEsylAtE As A trEAtmENt for mEtAstAtiC BrEAst CANCEr iN sPAiN: mANAgEmENt iN thE lAtEr liNEs of thErAPy
Majethia U. 1 , Tremblay G. 2 , Kontoudis I. 3 , DeRosendo J. 4 1 Eisai Inc., Woodcliff Lake, NJ, USA, 2 Eisai, Woodcliff Lake, NJ, USA, 3 Eisai Europe Ltd., Hatfield, UK, 4 Eisai Farmacéutica, S.A., Madrid, Spain OBJECTIVES: The objective of this study was to estimate Incremental Cost-Effectiveness Ratio (ICER) of utilizing eribulin for Metastatic Breast Cancer (MBC) in Spain for the second line (2L) treatment of HER2 negative (HER2NEG) patients. METHODS: Eribulin is indicated for the treatment of patients with locally advanced or MBC who have progressed following one prior chemotherapeutic regimen (FOPC). An economic model was developed to evaluate the cost-effectiveness of eribulin in HER2NEG MBC FOPC population in Spain. The data on progression free survival and overall survival was derived from randomized clinical trial of eribulin against capecitabine (study 301). A five year partitioned survival model was developed to estimate the ICER of the patients in this sub-group. Health state utility data was obtained by mapping quality of life collected in study 301 to EQ-5D using validated algorithm. Frequencies of adverse events and utilization of direct medical resources were also obtained from study 301. Local Spain tariffs were applied for all costs i.e. drug, administration, adverse event treatment, and direct medical costs including hospitalization, physician visits, end of life and palliative care. RESULTS: Incremental life years (LYs) and Quality Adjusted Life Years (QALYs) gained by these patients were 0.26 and 0.23 respectively. At a cost of eribulin of € 320 per vial, the ICERs per LY and QALY saved were € 32,865 and € 36,951 respectively. Sensitivity analysis results were also consistent with the basecase findings. CONCLUSIONS: According to reviewed HTA decisions in the past, eribulin was found to be costeffective in 2L HER2NEG populations. Given the limited number of effective therapeutic options available to these patients, cost effective eribulin represents a valid option for optimizing the treatment pathways.
